Industry Focus

Motley Fool analysts dig into Teva Pharmaceuticals recent M&A and debate the single most important number reported in Gilead Sciences second quarter earnings results.

Direct download: 150729_IF_Healthcare.mp3
Category:Podcast -- posted at: 12:00pm EST